Citizens JMP raises Hinge Health stock price target to $65 on strong earnings

Hinge Health (HNGE) reported robust Q1 results, significantly surpassing consensus estimates with $139.1 million in revenue (55% YoY growth) and a strong non-GAAP operating margin of 18.8%. The digital health company's stock surged 8% after-hours and is up 63% from its IPO, outperforming the Russell 3000. Analysts, including Citizens JMP which raised its price target to $65, maintain positive ratings, citing Hinge Health's market leadership and growth prospects, though InvestingPro suggests the stock is currently trading above its fair value.

Analysis

Hinge Health (HNGE) delivered an exceptionally strong quarterly performance, significantly exceeding market expectations and reinforcing a bullish analyst consensus. The company reported revenue of $139.1 million, a 55% year-over-year increase that surpassed consensus estimates by over 10%, and billings of $196.6 million, which beat analyst forecasts by a wide margin. Most notably, Hinge Health demonstrated powerful operating leverage, posting a non-GAAP operating margin of 18.8% against a consensus of just 3.1%, leading to a non-GAAP EPS of $0.33, nearly four times the expected $0.09. This robust fundamental performance triggered an 8% after-hours stock gain and highlights its sustained outperformance since its public offering, with shares up 63% versus the Russell 3000's 9% gain. The positive outlook is echoed by multiple analysts, including Citizens JMP, which raised its price target to $65.00, and Raymond James, which anticipates over 20% annual revenue growth. However, this strong momentum and positive sentiment are tempered by valuation concerns, as InvestingPro analysis indicates the stock is currently trading above its fair value despite a low reported P/E of 9.86.

Key Decisions for Investors

• The significant beat on revenue and, more critically, on operating margin and EPS, supports a bullish case for growth-focused investors, as it signals strong execution and profitability potential.
• Investors should weigh the company's impressive operational momentum and positive analyst ratings against its valuation, given the stock's 63% appreciation since its IPO and indications that it may be trading above its intrinsic fair value.
• The planned 2026 implementation of the HingeSelect provider network is a key long-term catalyst to monitor, as its success could further solidify market leadership and justify the premium valuation.